Skip to main content
ERYTECH Pharma S.A. logo

ERYTECH Pharma S.A. — Investor Relations & Filings

Ticker · ERYP ISIN · FR001400K4B1 LEI · 969500U8ZZCODU8A9374 PA Manufacturing
Open in API
Filings indexed 864 across all filing types
Latest filing 2023-10-24 Regulatory Filings
Country FR France
Listing PA ERYP

About ERYTECH Pharma S.A.

https://phaxiam.com/

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Recent filings

Filing Released Lang Actions
PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus
Regulatory Filings Classification · 1% confidence The document is a press release dated October 24, 2023, announcing that PHAXIAM Therapeutics has obtained regulatory authorizations (from ANSM and Ethics Committee) to launch a Phase 1 clinical study for endocarditis infections. It details the study design, patient recruitment timeline, and expected results. This type of announcement, focusing on clinical trial progress, regulatory milestones, and business updates, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a formal announcement of a significant operational/clinical development, and not a full financial report (10-K, IR) or a transcript (CT), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS). Given the content is a specific, time-sensitive operational update (clinical trial approval), and not a general regulatory notice, ER is often used for such material news releases, although RNS is the general fallback. However, since it is a specific operational update that is not a formal financial report, and it doesn't fit the other specific categories (like DIRS, DIV, CAP), RNS (Regulatory Filings/General Announcement) is the most appropriate general classification for material, non-standardized corporate news releases that aren't explicitly ERs or CTs, especially when the content is about clinical progress rather than financial results highlights. Given the context of a press release announcing a major clinical step, RNS is the safest general classification for material, non-financial-summary announcements.
2023-10-24 English
TP ICAP Midcap initie à l’achat la couverture de PHAXIAM Therapeutics
Regulatory Filings Classification · 1% confidence The document is a press release dated October 23, 2023, announcing that TP ICAP Midcap initiated research coverage on PHAXIAM Therapeutics with a 'Buy' recommendation and a price target. This type of announcement, which details the initiation of analyst coverage or a research report, is typically classified as a general regulatory announcement or a specific type of investor relations communication. It is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT). Since it is an announcement related to investor information (analyst coverage initiation), and it is structured as a formal press release ('COMMUNIQUE DE PRESSE'), it fits best under the general category for regulatory announcements that don't have a more specific code, or potentially Investor Presentation (IP) if it were a presentation, but here it is an announcement *about* a report. Given the options, and that it is a formal communication about market perception/analysis, it is most closely aligned with a general Regulatory Filing (RNS) as a fallback, or potentially an Investor Presentation (IP) if the analyst report itself was attached or summarized extensively, but the text focuses on the *announcement* of the initiation. Since it is a press release announcing external analyst coverage, RNS (Regulatory Filings/General Announcement) is the most appropriate general classification for this type of market-moving news that isn't a core financial filing.
2023-10-23 French
TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation
Regulatory Filings Classification · 1% confidence The document is a press release dated October 23, 2023, announcing that TP ICAP Midcap initiated coverage of PHAXIAM Therapeutics with a 'Buy' recommendation. This type of announcement, which relays external analyst coverage or market commentary rather than official company financial results (ER, IR, 10-K) or mandatory regulatory filings (like insider trades or capital changes), typically falls under general investor relations communication. Since there is no specific category for 'Analyst Coverage Initiation,' and it is not a formal report, a proxy statement, or a management discussion, the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as a general announcement category for non-standard, yet material, corporate news. The document length (5367 chars) is substantial enough that it is not just a brief link announcement (RPA), but it is not a core financial report.
2023-10-23 English
Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Monthly information related to total number of voting rights and shares composing the share capital - September 30, 2023." It explicitly references Article 223-16 of the French Autorité des Marchés Financiers (AMF) regulation and provides a table detailing the monthly evolution of the total number of shares and voting rights. This type of regular disclosure concerning the capital structure and voting rights is a specific regulatory requirement, often falling under general regulatory announcements or specific capital/share notifications. Since the document is a direct report of voting rights data, it is not a general announcement of a report (RPA) or a general regulatory filing (RNS). It is most closely related to changes in share capital or major shareholding notifications, but the specific focus on 'voting rights' and 'shares composing the share capital' makes it a unique disclosure. Given the options, it is a specific regulatory disclosure about the share structure. While 'SHA' (Share Issue/Capital Change) is close, this is a recurring monthly disclosure of the *current* state of voting rights, not necessarily an announcement of a change event. However, in many classification schemes, recurring reports on share capital structure fall under capital change/share information. Since it is a direct, periodic report on the share capital structure and voting rights, and not a general announcement, it fits best under a category related to share structure or a specific regulatory filing. Given the options, and recognizing this is a mandatory disclosure about the composition of capital and voting rights, it is a specific regulatory filing. Since there isn't a perfect 'Voting Rights Disclosure' code, and it is a direct report, we must choose the closest fit. It is not a DVA (Declaration of Voting Results from a meeting). It is a direct report on the capital structure. If we must choose from the list, and considering it is a direct report of share capital composition, 'SHA' (Share Issue/Capital Change) is the closest category related to the underlying data, although it is a monthly update rather than a singular event announcement. However, the content is purely statistical reporting on the share base, which is often grouped with capital structure updates. Given the highly specific nature of the data (voting rights count), and its regulatory origin (AMF), it is a specific regulatory filing. Since it is a direct report and not an announcement of a report, and it deals directly with the share capital base, SHA is a plausible fit, but RNS (Regulatory Filings) is the safest fallback for specific, non-standard regulatory reports. Let's re-evaluate: This is a mandatory monthly disclosure of the total number of shares and voting rights. This is a fundamental piece of information about the company's capital structure. 'SHA' covers 'Share Issue/Capital Change'. This report *reflects* the result of any changes. Given the options, and the fact that it is a direct report, I will classify it as a specific regulatory filing that doesn't fit the main categories, leaning towards RNS, or if we strictly interpret the content as reflecting the capital base, SHA. Since it is a direct, periodic report mandated by a regulator, and not an announcement of a report, RNS is the most appropriate fallback for specific regulatory data disclosures not covered elsewhere. I will use RNS as the most accurate general regulatory filing code for this specific monthly report type.
2023-10-23 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 30 septembre 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 30 septembre 2023" and explicitly references Article 223-16 of the AMF (Autorité des Marchés Financiers) General Regulation. This structure—a monthly update on the total number of voting rights and shares—is characteristic of regulatory disclosures concerning capital structure changes or major shareholdings thresholds, often required monthly in France. While it relates to share capital, it is not a formal share issue announcement (SHA) or a major shareholding notification (MRQ) which typically reports crossing a specific threshold. It is a routine regulatory disclosure about the total voting rights base. Given the options, this type of routine regulatory disclosure about voting rights and share capital count, mandated by financial authorities, fits best under the general 'Regulatory Filings' (RNS) category, as it is a specific, recurring regulatory report that doesn't match the other specialized codes like DIV, SHA, or MRQ precisely, although it touches upon share capital. Since it is a formal, mandated regulatory report, RNS is the most appropriate fallback.
2023-10-23 French
PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains
Earnings Release Classification · 1% confidence The document is a press release dated October 9, 2023, announcing scientific data regarding the high coverage performance of PHAXIAM Therapeutics' anti-Staphylococcus aureus phages based on testing using their phagogram (an in vitro diagnostic test). This type of announcement, detailing recent scientific findings, clinical trial results, or product performance updates, is characteristic of an Earnings Release (ER) if it were tied to a reporting period, or more generally, a corporate update. Since it is a specific announcement of positive operational/scientific data rather than a formal financial report (like 10-K or IR), and it is presented as a news release, it fits best under the 'Earnings Release' category (ER) which often encompasses key operational highlights released outside of the formal quarterly/annual filings, or potentially 'Regulatory Filings' (RNS) if it were a mandatory disclosure. Given the structure—headline, key data points, CEO quote, and boilerplate about the company—it strongly resembles an Earnings Release (ER) announcing operational/scientific progress, even if it's not explicitly tied to a quarterly earnings period. It is not a full financial report (10-K, IR), a transcript (CT), or a presentation (IP). Therefore, ER is the most appropriate classification for a significant operational/scientific announcement presented as a press release. FY 2023
2023-10-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.